Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management

Title	Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management
Authors	Bryan Oronsky, Scott Caroen, Arnold Oronsky, Vaughn E. Dobalian, Neil Oronsky, Michelle Lybeck, Tony R. Reid, Corey A. Carter
Magazine	Cancer Chemotherapy and Pharmacology
Date	07/20/2017
DOI	10.1007/s00280-017-3392-8
Introduction	Platinum-based chemotherapy, particularly cisplatin, often results in electrolyte imbalances such as hypomagnesaemia, hypokalaemia, hypophosphataemia, hypocalcaemia, and hyponatraemia. This review aims to consolidate existing literature, clarify the mechanisms behind these imbalances, and outline clinical manifestations and management strategies. Oncologists and primary care physicians must accurately diagnose and treat these conditions to improve patient outcomes. Understanding the nuances of platinum-induced electrolyte disturbances is crucial for providing optimal care to cancer patients.
Quote	Bryan Oronsky, Scott Caroen and Arnold Oronsky et al. Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management. Cancer Chemotherapy and Pharmacology. 2017. Vol. 80(5):895-907. DOI: 10.1007/s00280-017-3392-8
Element	Platinum (Pt)
Industry	Chemical & Pharmacy